Back to Authors

Murry, Charles E.

0000-0003-3862-6773

Mayo Clinic

University of Southern California

Citations 2

Cell-type specific allelic dampening of sex-linked genes in sex chromosome aneuploidy
Filippova, G. N. , Sanger, Elliott M., MacDonald, James, Fang, He, Groneck, Camille, Takasaki, Masaya, Meleshko, A. N., Liu, Yajuan , Li, Gang , Dyke, Daniel Van, Gravholt, Claus H., Bammler, Theo K. , Young, Jessica E., Berletch, Joel B. , Van Dyke, Daniel, Gravholt, Claus H , Noble, William S , Deng, Xinxian , Berletch, Joel B , Sanger, Elliott, Fang, He, Ma, Wenxiu , ZHANG, RAN, Murry, Charles E. , Dyke, Daniel L. Van , Skakkebæk, Anne , Gravholt, Claus Højbjerg , Distèche, Christine M.

No container title available | April 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.16.719032 Get It

Common sex chromosome aneuploidies (SCAs) often present with cognitive and cardiovascular dysfunction in humans. To address SCA effects on gene expression and DNA methylation in relevant cell types, we differentiated neural precursor cells (NPCs) and cardiomyocytes (CMs) from human induced pluripotent stem cells (hiPSCs) with different numbers of sex chromosomes, including isogenic and independent lines. As expected, the expression of genes that escape X inactivation (escapees) mostly increases with the number of inactive X chromosomes (Xi). However, allelic analysis shows dampening of escapees specifically on the Xi in XXY compared to XX in both NPCs and CMs, revealing a novel type of dosage compensation in SCA. In contrast, Y-linked gene expression is higher in XXY versus XY NPCs, but the opposite is observed in CMs. This may explain the greater number of differentially expressed autosomal genes in NPCs versus CMs with an added Y chromosome, while effects of added X chromosomes are similar between cell types. Concordantly, changes in autosomal DNA methylation are mainly driven by the presence of a Y chromosome. These findings highlight the cell-type specificity of sex-linked and autosomal gene regulation in SCA conditions.
Transgenic overexpression of ribonucleotide reductase improves cardiac performance
Nowakowski, Sarah G., Kolwicz, Stephen C. , Korte, F. Steven, Luo, Zhaoxiong, Robinson-Hamm, Jacqueline N. , Page, Jennifer L. , Brozovich, Frank V. , Tian, Rong , Weiss, Robert S. , Murry, Charles E. , Regnier, Michael , Brozovich, Frank V

Proceedings of the National Academy of Sciences | March 27, 2013 | Volume: 110 | Issue: 15 | Pages: 6187-6192

10.1073/pnas.1220693110 Get It

We previously demonstrated that cardiac myosin can use 2-deoxy-ATP (dATP) as an energy substrate, that it enhances contraction and relaxation with minimal effect on calcium-handling properties in vitro, and that contractile enhancement occurs with only minor elevation of cellular [dATP]. Here, we report the effect of chronically enhanced dATP concentration on cardiac function using a transgenic mouse that overexpresses the enzyme ribonucleotide reductase (TgRR), which catalyzes the rate-limiting step in de novo deoxyribonucleotide biosynthesis. Hearts from TgRR mice had elevated left ventricular systolic function compared with wild-type (WT) mice, both in vivo and in vitro, without signs of hypertrophy or altered diastolic function. Isolated cardiomyocytes from TgRR mice had enhanced contraction and relaxation, with no change in Ca 2+ transients, suggesting targeted improvement of myofilament function. TgRR hearts had normal ATP and only slightly decreased phosphocreatine levels by 31 P NMR spectroscopy, and they maintained rate responsiveness to dobutamine challenge. These data demonstrate long-term (at least 5-mo) elevation of cardiac [dATP] results in sustained elevation of basal left ventricular performance, with maintained β-adrenergic responsiveness and energetic reserves. Combined with results from previous studies, we conclude that this occurs primarily via enhanced myofilament activation and contraction, with similar or faster ability to relax. The data are sufficiently compelling to consider elevated cardiac [dATP] as a therapeutic option to treat systolic dysfunction.